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Abstract
Type2diabetes is the fastestgrowingmetabolicdisease in theworld.Recently,muscle is consideredanendocrineorganwhichsecretes
various peptides that play an important role in insulin resistance and metabolic syndrome. We assessed 4 different myokines, irisin,
interleukin-13 (IL-13), follistatin-related protein-1 (FSTL-1), and fractalkine, in normal, prediabetes, and diabetes patients.
A total of 126 participants who visited Gangnam Severance Hospital were enrolled and divided into normal, prediabetes, and
diabetes groups based on oral glucose tolerance test and hemoglobin a1c. A cross-sectional study was conducted to measure and
compare serum levels of irisin, IL-13, FSTL-1, and fractalkine among the groups.
Irisin level showed a tendency to increase in prediabetes group compared to normal group (P< .1) but showed a significant
decrease when comparing diabetes from prediabetes group (P< .001). IL-13 decreased in diabetes group compared to prediabetes
and normal group (P< .001, P< .05, respectively). FSTL-1 of diabetes group was lower than that of prediabetes group (P< .05), and
fractalkine was higher in diabetes group compared to that of prediabetes and normal group (P< .01, P< .01, respectively).
Irisin, IL-13, and FSTL-1 levels were reduced in diabetes group compared to normal or prediabetes group while fractalkine showed
a progressive increase from normal to diabetes group. Further studies are warranted to study the roles of variousmyokine in diabetes
through a larger prospective study.
Abbreviations: BMI = body mass index, DBP = diastolic blood pressure, DM = type 2 diabetes, FPG = fasting plasma glucose,
FSTL = follistatin-related protein, HbA1c = glycated hemoglobin, HDL-C = high-density lipoprotein cholesterol, HOMA-IR =
homeostasis model assessment of insulin resistance, IL-13 = interleukin-13, LDL-C = low-density lipoprotein cholesterol, NGT =
normal glucose tolerance, OGTT = oral glucose tolerance test, PPG = postprandial glucose, preDM = prediabetes, SBP = systolic
blood pressure, TC = total cholesterol, TG = triglyceride.
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Type 2 diabetes is the fastest growing metabolic disease in the
world which involves various organs. There are about 4.8 million
(13.7%) Korean adults diagnosed with diabetes mellitus, andEditor: Liang-Jun Yan.
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1about 8.3 million (24.8%) Korean adults with impaired fasting
glucose. With this trend, it is estimated that the number of
diabetes patients will increase to 5.9 million by 2050 in
Korea.[1,2]
Various studies have been conducted on the importance of
muscle in the development of diabetes and insulin resistance.
Similar to adipokines secreted from adipose tissue, myokines
secreted from muscle are involved in insulin resistance and
metabolic syndrome.[3,4] Myokine is a hundreds of proteins
secreted by myocytes following muscular contraction, and
myokine receptors are found in muscle, liver, fat, and pancreas
which play an important role in glucose metabolism. Irisin is one
of the earliest and most studied myokines, but its relation to
blood glucose, lipid, or metabolic syndrome is still controver-
sial.[5–12] After irisin, a variety of new myokine has been
discovered, but not many studies have been conducted yet.
The purpose of this study is to compare the myokine levels in
normal, prediabetes, and diabetes patients and to analyze their
clinical significance.2. Methods
2.1. Subjects
A total of 126 participants who visited the Gangnam Severance
Hospital were enrolled. Eligible patients were men and women
between the ages of 20 and 75 who underwent 75g oral glucose
tolerance test (OGTT) and glycated hemoglobin (HbA1c) test.
Participants were divided into 3 groups by American Diabetes
Table 1
Baseline characteristics of participants according to diabetes
stages.
Normal Prediabetes Diabetes P
N 19 36 71
Age (yrs) 43.2±11.8 52.6±11.7
∗
57.8±12.9
∗
<.01
Sex (M/F) 9/10 22/14 48/23
SBP (mm Hg) 126.5±16.0 121.3±25.6 122.7±12.0 NS
DBP (mm Hg) 77.8±8.5 78.2±16.0 77.2±8.6 NS
BMI (kg/m2) 24.1±2.7 23.8±5.5 24.4±2.9 NS∗ ∗,†
Park et al. Medicine (2020) 99:8 MedicineAssociation diagnostic guidelines: normal, prediabetes, and
diabetes group. Patients with estimated glomerular filtration
rate <30mL/min/1.73m2, aspartate aminotransferase/alanine
aminotransferase>3 times greater the upper normal limit, taking
glucocorticoids or any herbal medicine within the past 3 months,
chronic inflammatory disease in the active phase or acute
infection status, and pregnant or lactating women were excluded.
This study was approved by the Institutional Review Board of
Gangnam Severance Hospital (3-2006-0005).FPG (mg/dL) 93.44±6.04 105.50±10.43 140.83±40.71 <.01
1hr PPG (mg/dL) 130.22±41.24 170.25±61.22
∗
277.72±75.23
∗,† <.01
2hr PPG (mg/dL) 106.22±19.20 140.02±33.93
∗
266.42±86.64
∗,† <.01
HbA1c (%) 5.33±0.35 5.96±0.79
∗
7.34±1.55
∗,† <.01
TC (mg/dL) 183.81±31.28 181.22±36.87 181.40±34.97 NS
TG (mg/dL) 109.07±46.36 118.11±68.05 132.64±129.80 NS
HDL-C (mg/dL) 50.42±10.63 48.00±12.07 47.38±13.36 NS
LDL-C (mg/dL) 118.61±26.21 112.11±30.14 110.44±32.37 NS
HOMA-IR 1.70±1.36 2.26±2.02 3.11±2.40 NS
Data are mean± standard deviation.
BMI=body mass index, DBP=diastolic blood pressure, FPG= fasting plasma glucose, HbA1c=
glycated hemoglobin, HDL-C=high-density lipoprotein cholesterol, HOMA-IR=homeostasis model
assessment of insulin resistance, LDL-C= low-density lipoprotein cholesterol, NS=not significant,2.2. Clinical characteristics
Height and weight were measured, and body mass index (BMI)
was calculated by dividing the weight (kg) by the square of the
height (m2). Systolic and diastolic blood pressures were measured
by trained nurses with an automatic blood pressure monitor
(HEM-7080IC; Omron Healthcare, Lake Forest, IL). Lifestyle,
personal medical history of acute or chronic illness, and
medication history were assessed using a standard questionnaire.PPG=postprandial glucose, SBP= systolic blood pressure, TC= total cholesterol, TG= triglyceride.
∗
P< .05 compared to normal.
† P< .05 compared to prediabetes.
Table 2
Myokine levels according to diabetes stages.
Normal Prediabetes Diabetes P
N 19 36 71∗ †,‡2.3. Biochemical parameters
Blood samples were taken from the antecubital vein after at least
8hours of fasting. The fasting plasma glucose concentrations
were measured by a standard glucose oxidase method (747
Automatic Analyzer, Hitachi, Tokyo, Japan). Fasting serum
insulin was determined by chemiluminescence (RIA Kit, Daiichi,
Japan), and HbA1c was measured by high performance liquid
chromatography (Variant II, Bio-Rad, Hercules, CA). Triglycer-
ide, total cholesterol, and high-density lipoprotein cholesterol
were assessed using Hitachi 7600-120 automated chemistry
analyzer (Hitachi 747, Tokyo, Japan). Calculation of low-density
lipoprotein cholesterol was done using the Friedewald formula.
A standard 75g OGTT was also performed, and plasma
glucose and insulin levels were measured in venous blood
collected at 0, 60, and 120minutes after ingestion. Insulin
resistance was estimated using HOMA equations as follows:
homeostasis model assessment of insulin resistance (HOMA-
IR)= (fasting glucose [mg/dL] fasting insulin [mcIU/mL]/405).
Blood samples for myokine tests were taken after 8hours of
fasting and were immediately centrifuged, and serum samples
were analyzed for interleukin-13 (IL-13, abcam [ab46038]),
fractalkine (R&D [DCX310]), follistatin-related protein-1
(FSTL-1, Boster Immuoleaders [EK0965]), and irisin (Phoenix
[EK-067-16]) using enzyme-linked immunosorbent assay.
2.4. Statistical analysis
Statistical analysis was performed using SPSS version 23.0 for
Windows (SPSS Inc, Chicago, IL). All data were presented as
mean± standard deviation. The intergroup comparisons were
performed using analysis of variance tests. The relationships
between myokine and various clinical parameters were examined
using Pearson correlation. A value of P< .05 was considered
statistically significant.Irisin (ng/mL) 175.61±46.28 202.50±54.67 128.43±38.24 <.01
IL-13 (pg/mL) 29.66±7.43 33.46±18.35 20.04±14.09†,‡ <.01
FSTL-1 (ng/mL) 400.62±159.59 497.56±340.0 350.86±220.63‡ <.05
Fractalkine (ng/dL) 360.05±107.89 379.28±186.60 522.79±210.86†,‡ <.01
Data are mean± standard deviation.
FSTL= follistatin-related protein, IL= interleukin.
∗
P< .1 compared to normal.
† P< .05 compared to normal.
‡ P< .05 compared to prediabetes.3. Results
3.1. Baseline characteristics
Themean age of subjects was 54±13 years, and 62.7%weremen
(n=79). Subjects were stratified into 3 groups according to their
glycemic status. The biochemical parameters and clinical2characteristics are presented in Table 1. Age, fasting plasma
glucose (FPG), postprandial glucose (PPG), and HbA1c were
elevated in prediabetes and diabetes groups.3.2. Myokine at different stages of diabetes
Circulating myokine levels according to glycemic status are
presented in Table 2 and Figure 1. Serum irisin level showed a
tendency to increase in prediabetes group compared to normal
group (P< .1), but it was reduced in diabetes group compared to
prediabetes group (P< .001). Ultimately, irisin was significantly
lower in diabetes group compared to both the prediabetes and
normal group (P< .001, P< .001, respectively). IL-13 was
reduced in diabetes group compared to prediabetes and normal
glucose group (P< .001, P< .05, respectively), and FSTL-1 was
lower in diabetes group compared to prediabetes group (P< .05).
Fractalkine was higher in diabetes group compared to prediabe-
tes and normal glucose group (P< .01, P< .01, respectively), and
it showed a progressive increase with the deterioration of
glucose control.
Also, irisin and IL-13 showed negative correlations with FPG,
PPG, and HbA1c (all P< .001, all P< .05, respectively).
Fractalkine showed positive correlation with FPG, PPG, and
HbA1c (all P< .001).
Figure 1. (A) Irisin, (B) IL-13, (C) FSTL-1, and (D) fractalkine levels according to diabetes stages. DM= type 2 diabetes, FSTL= follistatin-related protein, IL=
interleukin, NGT=normal glucose tolerance, preDM=prediabetes.
Park et al. Medicine (2020) 99:8 www.md-journal.com3.3. Association between changes of myokine and
glycemic status
All 4 myokines, irisin, IL-13, FSTL-1, and fractalkine consistently
showed statistically significant differences between subject with
prediabetes and diabetes.Multivariate logistic regression analysis
revealed that diabetes group had lower irisin and IL-13 compared
to prediabetes group after adjusting for sex, age, BMI, HbA1c,
and HOMA-IR (Table 3).
4. Discussion
In the present study, we noticed a significant association between
myokine levels and glycemic status in Korean adults. Even after
adjusting for various metabolic parameters, there were indepen-
dent associations between diabetes status and irisin and IL-13. ToTable 3
Odds ratios and 95% confidence intervals for myokine levels of diab
Irisin IL-13
OR (95% CI) P OR (95% CI)
Model 1 0.969 (0.957–0.981) <.001 0.951 (0.925–0.978) <
Model 2 0.968 (0.955–0.980) <.001 0.955 (0.929–0.982) .00
Model 3 0.974 (0.960–0.989) .001 0.965 (0.935–0.997) .03
Model 4 0.971 (0.955–0.988) .001 0.961 (0.925–0.998) .04
Model 1: Unadjusted.
Model 2: Adjusted for age and sex.
Model 3: Model 2+HbA1c.
Model 4: Model 3+BMI, HOMA-IR.
BMI=body mass index, CI= confidence interval, FSTL= follistatin-related protein, HbA1c=glycated hem
significant, OR=odds ratio.
3the best of our knowledge, this is probably the first human study
to reveal the association of diabetes status and various myokine
other than irisin.
Muscle tissue has been recently recognized as another
endocrine regulator of metabolism. Irisin, whose expression is
induced by peroxisome proliferator-activated receptor-g coac-
tivator 1a and exercise, is known to act on white adipocytes and
conversion to brown adipocytes, resulting in increase of
thermogenesis and energy expenditure, improvement of insulin
sensitivity and glucose tolerance, and reduction in body weights
in animal study and in vitro study.[13] Although a lot of human
researches on irisin have been done in recent years, the results are
still controversial. Stengel et al[14] reported positive correlation
between irisin levels and BMI in 40 participants whose BMI were
between 12.6 and 36.9kg/m2. Park et al[11] also reported positiveetes compared with prediabetes.
FSTL-1 Fractalkine
P OR (95% CI) P OR (95% CI) P
.001 0.998 (0.997–1.000) .014 1.004 (0.001–1.006) .002
1 0.998 (0.997–1.000) .043 1.004 (0.001–1.006) .002
0 0.998 (0.996–1.000) NS 1.002 (0.999–1.004) NS
2 0.998 (0.996–1.000) NS 1.002 (0.999–1.005) NS
oglobin, HOMA-IR=homeostasis model assessment of insulin resistance, IL= interleukin, NS=not
Park et al. Medicine (2020) 99:8 Medicinecorrelation between irisin levels and BMI, blood pressure, fasting
plasma glucose, triglyceride, and HOMA-IR, and showed that
irisin was an independent marker of metabolic syndrome in 151
participants. On the other hand, there are several studies
reporting that irisin showed low levels in diabetes or metabolic
syndrome patients, and Li et al[15] reported decreased irisin in
diabetes was independently associated with elevated advanced
glycation end products.[5,6,9]
In our study, irisin showed increasing tendency from normal to
prediabetes group (P< .1), then decreased significantly as
diabetes progressed further (P< .001), despite of no significant
difference of BMI and HOMA-IR among the 3 groups. Chen
et al[16] reported obese acanthosis nigricans patients, character-
izing hyperinsulinemia, showed higher irisin levels compared to
obese patients without acanthosis nigricans. Huerta et al[17]
researched irisin levels in 73 healthy overweight/obese women
without diabetes, and reported their high irisin levels decreased
with weight loss. Both studies suggested that the increase of irisin
may be due to the compensatory protective response against early
glucose impairment and impaired beta cell function. Initial
increasing tendency of irisin in our study can be thought of as a
result of these compensatory protective effects, and patients who
already had diabetes showed significantly lower irisin levels, since
these protective effects do not remain. This is the first time that
irisin levels have been analyzed with dividing into 3 groups.
IL-13 is known to increase the glucose uptake by skeletalmuscle,
oxidation, and glycogen synthesis via an Akt-dependent mecha-
nism. However, muscles of diabetes patients express more
microRNA let-7a and let-7d, which are direct translational
repressors of the IL-13 gene and result in lower serum IL-13.[18]
Moreover, Rutti et al[19] conducted ex vivo study using human and
rat islets and reported that IL-13 protects beta-cells from IL-1b
induced apoptosis, a cytokine known to play an important role in
type 2 diabetes. They suggested that IL-13 shows beneficial effect
on glucose homeostasis by preserving beta-cell mass.[19] There is
little human study about IL-13 and glucosemetabolism.One study
reported that IL-13 levels were higher in insulin-resistant patients
and correlated with hyperglycemia by cross-sectional study with
92 nondiabetes participants.[20] In our study, IL-13 was slightly
higher in prediabetes group compared to normal control group
(33.46pg/mL, 29.66pg/mL, respectively), but it failed to show
statistically significance. Instead, we confirmed that IL-13 of
diabetes patients decreased strongly and showed negative
correlation with FPG, PPG, and HbA1c. In addition, IL-13 also
had an independent association with diabetes, as a result of
regression analysis. Similar to irisin, IL-13 may show a
compensatory increase in prediabetes statewhere insulin resistance
is the main pathophysiology, and then decreases significantly with
the insulin secretory defect seen in diabetes.
FSTL-1, another myokine secreted from skeletal muscles,
stimulates muscle glucose uptake via AMP-activated protein
kinase activation in muscle cells.[21,22] Therefore, FSTL-1 is
thought to be related with glucose homeostasis, and expected to
help diabetes treatment in the future as insulin-independent
glucose uptake regulators, but no human research has been
conducted yet. In our study, FSTL-1 of diabetes group was lower
than that of prediabetes group.
Fractalkine is known to increase beta cell insulin secretion in ex
vivo and mice study by Lee et al.[23] Shah et al reported obesity
was related with higher fractalkine levels in vitro study, and
showed fractalkine levels were increased in patients with type 2
diabetes compared to nondiabetes.[24] Recently, Baldane et al4also showed that fractalkine levels were higher in newly
diagnosed diabetes patients, using 33 diabetes patients and 34
normal glucose tolerance subjects.[25] Our study showed that
diabetes group not only had higher fractalkine levels than normal
glucose group, but also higher than prediabetes group. In
addition, fractalkine showed strong positive correlation with
FPG, PPG, and HbA1c (all P< .001).
This study has several limitations. First, the number of study
participants is small and needs a larger sample size to confirm the
relationship. Furthermore, due to especially a small number of
normal glucose group subjects, the change between normal
glucose group and prediabetes group has not been sufficiently
analyzed. In addition, establishing a cause–effect relationship was
not possible due to the cross-sectional design of our study. In spite
of the above limitations, this study has significant implications
that are clinically relevant, as it is the first to investigate various
myokine in 3 groups according to the glycemic status.
In conclusion, we found that irisin increased in early glycemic
impairment possibly by compensatory protective response and
decreased after diabetes progression by analyzing it in 3 groups.
IL-13 and FSTL-1, which lacked human research, showed low
levels in diabetes patients in this study. In particular, IL-13
showed a negative correlation with glycemic parameters such as
FFP, PPG, and HbA1c, and was suggested that it could be used as
an independent predictive marker. Fractalkine was in line with
previous studies that it showed higher levels in diabetes compared
to normal glycemic subjects. In addition to this, we included
prediabetes group in our study and found that fractalkine levels
increased progressively among 3 groups. It also showed strong
positive correlation with glycemic parameters such as FFP, PPG,
and HbA1c.
This study suggests that each myokine may have various
responses and roles in glycemic metabolic impairment, and it is
necessary to study the roles of various myokine in diabetes
through a larger prospective study.Author contributions
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